Invesco Ltd.: OPITQ position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Invesco Ltd. on OPITQ, newest first. How the timeline and the estimate are built.
Invesco Ltd. held 0 OPITQ shares at 2025-12-31 per its 13F-HR filed 2026-02-19.
the latest 13F is the newest step
- period ended2025-12-3113F/A 0 sharesChange vs previous 13F -153,868 shares
13F-HR 0000914208-26-000071 filed by Invesco Ltd.
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2025-09-3013F 153,868 sharesChange vs previous 13F -157,901 shares
<0.01% of the 13F portfolio, value $50,653.
13F-HR 0000914208-25-000430 filed by Invesco Ltd.
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 311,769 sharesChange vs previous 13F -178,193 shares
<0.01% of the 13F portfolio, value $77,007.
13F-HR 0000914208-25-000341 filed by Invesco Ltd.
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 489,962 sharesChange vs previous 13F -152,777 shares
<0.01% of the 13F portfolio, value $223,423.
13F-HR 0000914208-25-000230 filed by Invesco Ltd.
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-12-3113F 642,739 sharesChange vs previous 13F -1,119,201 shares
<0.01% of the 13F portfolio, value $642,610.
13F-HR 0000914208-25-000103 filed by Invesco Ltd.
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2024-09-3013F 1,761,940 sharesChange vs previous 13F not available
<0.01% of the 13F portfolio, value $3,841,029.
13F-HR 0000914208-24-000547 filed by Invesco Ltd.
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).